← Back to Search

Behavioral Intervention

Motion Reset for Cybersickness in Virtual Reality

N/A
Waitlist Available
Led By Susan Persky, Ph.D.
Research Sponsored by National Human Genome Research Institute (NHGRI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal or corrected-to-normal hearing
Aged 18-60
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during and after vr use

Summary

"This trial aims to test a new software called Motion Reset designed to reduce symptoms of cybersickness in people using virtual reality (VR). Healthy adults aged 18 to 60 will participate in a clinic

Who is the study for?
This trial is for healthy adults aged 18 to 60 who are interested in participating in a study involving virtual reality (VR). The goal is to see if new software can help prevent the discomfort some people feel after using VR, known as cybersickness.
What is being tested?
The trial tests Motion Reset software designed to reduce symptoms of cybersickness against a placebo during VR use. Participants will be divided into groups; one with prevention-focused VR experience, another without it, and a control group with no VR.
What are the potential side effects?
Since this study involves healthy volunteers using VR technology, potential side effects may include eye strain, nausea, dizziness or headaches associated with cybersickness. These symptoms are typically mild and resolve after stopping VR use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My hearing is normal or corrected to normal.
Select...
I am between 18 and 60 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during vr use
This trial's timeline: 3 weeks for screening, Varies for treatment, and during vr use for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
self-reported cybersickness
Secondary study objectives
discontinuation of VR use

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Intervention: Motion ResetExperimental Treatment1 Intervention
Participate in virtual reality activities
Group II: No interventionActive Control1 Intervention
Group III: Placebo experiencePlacebo Group1 Intervention
Participate in virtual reality activities

Find a Location

Who is running the clinical trial?

National Human Genome Research Institute (NHGRI)Lead Sponsor
270 Previous Clinical Trials
293,869 Total Patients Enrolled
Susan Persky, Ph.D.Principal InvestigatorNational Human Genome Research Institute (NHGRI)
8 Previous Clinical Trials
4,336 Total Patients Enrolled
~100 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top